ALNY Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 19%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Biogen, Inc.'s return on equity of 9.36%.

Alnylam Pharmaceuticals, Inc. has a consensus price target of $490.50, signalling upside risk potential of 16.1%. On the other hand Biogen, Inc. has an analysts' consensus of $183.76 which suggests that it could fall by -1.69%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Biogen, Inc..

Alnylam Pharmaceuticals, Inc. has a beta of 0.325, which suggesting that the stock is 67.539% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.301%.

Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,756.76x while Biogen, Inc.'s PE ratio is 17.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 17.33x versus 2.83x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bristol Myers Squibb Co. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 17.96%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Alnylam Pharmaceuticals, Inc. has a consensus price target of $490.50, signalling upside risk potential of 16.1%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $55.09 which suggests that it could fall by -2.88%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Bristol Myers Squibb Co..

Alnylam Pharmaceuticals, Inc. has a beta of 0.325, which suggesting that the stock is 67.539% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.215%.

Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.39% to investors and pays a quarterly dividend of $0.63 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,756.76x while Bristol Myers Squibb Co.'s PE ratio is 19.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 17.33x versus 2.41x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -259.95%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Insmed, Inc.'s return on equity of -193.23%.

Alnylam Pharmaceuticals, Inc. has a consensus price target of $490.50, signalling upside risk potential of 16.1%. On the other hand Insmed, Inc. has an analysts' consensus of $215.11 which suggests that it could grow by 22.22%. Given that Insmed, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Alnylam Pharmaceuticals, Inc. has a beta of 0.325, which suggesting that the stock is 67.539% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.523%.

Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are larger than Insmed, Inc. quarterly revenues of $142.3M. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than Insmed, Inc.'s net income of -$370M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,756.76x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 17.33x versus 74.90x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 21.32%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Pfizer Inc.'s return on equity of 10.84%.

Alnylam Pharmaceuticals, Inc. has a consensus price target of $490.50, signalling upside risk potential of 16.1%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 13.22%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Alnylam Pharmaceuticals, Inc. has a beta of 0.325, which suggesting that the stock is 67.539% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.8% to investors and pays a quarterly dividend of $0.43 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,756.76x while Pfizer Inc.'s PE ratio is 14.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 17.33x versus 2.30x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.